✉ Email this page to a colleague
« Back to Dashboard
Isoquinoline is an investigational drug.
There have been 13 clinical trials for Isoquinoline. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2021.
The most common disease conditions in clinical trials are Cysticercosis, HIV Infections, and Taeniasis. The leading clinical trial sponsors are National Institute of Mental Health (NIMH), Jun Tao, and Centers for Disease Control and Prevention.
There are six hundred and five US patents protecting this investigational drug and forty-one international patents.
Recent Clinical Trials for Isoquinoline
|Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients||Tianjin Anding Hospital||Phase 4|
|Effect of Berberine Hydrochloride on Blood Pressure and Vascular Endothelial Function in Patients With Hypertension||Jun Tao||Phase 4|
|Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention||Peking Union Medical College Hospital||Phase 4|
Top disease conditions for Isoquinoline
Top clinical trial sponsors for Isoquinoline
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Isoquinoline||See Plans and Pricing||Quinazolinone and isoquinolinone derivative||CHUGAI SEIYAKU KABUSHIKI KAISHA (Tokyo, JP)||See Plans and Pricing|
|Isoquinoline||See Plans and Pricing||Hair dyeing process using at least one ortho-diphenol and one organic salt of titanium and of a carboxylic acid||L'OREAL (Paris, FR)||See Plans and Pricing|
|Isoquinoline||See Plans and Pricing||Methods and compositions for inhibition of Ras||ARAXES PHARMA LLC (San Diego, CA)||See Plans and Pricing|
|Isoquinoline||See Plans and Pricing||Humanized anti-Tn-MUC1 antibodies and their conjugates||ADC Therpeutics S.A. (Epalinges, CH) Medimmune Limited (Cambridge, GB)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Isoquinoline||China||CN105916963||2034-01-17||See Plans and Pricing|
|Isoquinoline||European Patent Office||EP3094703||2034-01-17||See Plans and Pricing|
|Isoquinoline||Japan||JP2017508728||2034-01-17||See Plans and Pricing|
|Isoquinoline||South Korea||KR20160103144||2034-01-17||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|